» Articles » PMID: 38091401

Parkinson's VPS35[D620N] Mutation Induces LRRK2-mediated Lysosomal Association of RILPL1 and TMEM55B

Abstract

We demonstrate that the Parkinson's VPS35[D620N] mutation alters the expression of ~220 lysosomal proteins and stimulates recruitment and phosphorylation of Rab proteins at the lysosome. This recruits the phospho-Rab effector protein RILPL1 to the lysosome where it binds to the lysosomal integral membrane protein TMEM55B. We identify highly conserved regions of RILPL1 and TMEM55B that interact and design mutations that block binding. In mouse fibroblasts, brain, and lung, we demonstrate that the VPS35[D620N] mutation reduces RILPL1 levels, in a manner reversed by LRRK2 inhibition and proteasome inhibitors. Knockout of RILPL1 enhances phosphorylation of Rab substrates, and knockout of TMEM55B increases RILPL1 levels. The lysosomotropic agent LLOMe also induced LRRK2 kinase-mediated association of RILPL1 to the lysosome, but to a lower extent than the D620N mutation. Our study uncovers a pathway through which dysfunctional lysosomes resulting from the VPS35[D620N] mutation recruit and activate LRRK2 on the lysosomal surface, driving assembly of the RILPL1-TMEM55B complex.

Citing Articles

Epigenetic regulation-mediated disorders in dopamine transporter endocytosis: A novel mechanism for the pathogenesis of Parkinson's disease.

Liang Z, Liu W, Cao M, Cui J, Lan J, Ding Y Theranostics. 2025; 15(6):2250-2278.

PMID: 39990232 PMC: 11840736. DOI: 10.7150/thno.107436.


Endogenous LRRK2 and PINK1 function in a convergent neuroprotective ciliogenesis pathway in the brain.

Bagnoli E, Lin Y, Burel S, Jaimon E, Antico O, Themistokleous C Proc Natl Acad Sci U S A. 2025; 122(5):e2412029122.

PMID: 39874296 PMC: 11804522. DOI: 10.1073/pnas.2412029122.


TMEM55A-mediated PI5P signaling regulates α-cell actin depolymerization and glucagon secretion.

Liu X, Dos Santos T, Spigelman A, Duckett S, Smith N, Suzuki K bioRxiv. 2025; .

PMID: 39763967 PMC: 11702586. DOI: 10.1101/2024.12.16.628242.


LRRK2 in Parkinson's disease: upstream regulation and therapeutic targeting.

Xiong Y, Yu J Trends Mol Med. 2024; 30(10):982-996.

PMID: 39153957 PMC: 11466701. DOI: 10.1016/j.molmed.2024.07.003.


Mechanisms of lysosomal tubulation and sorting driven by LRRK2.

Bonet-Ponce L, Kluss J, Cookson M Biochem Soc Trans. 2024; 52(4):1909-1919.

PMID: 39083004 PMC: 11668303. DOI: 10.1042/BST20240087.


References
1.
Berndsen K, Lis P, Yeshaw W, Wawro P, Nirujogi R, Wightman M . PPM1H phosphatase counteracts LRRK2 signaling by selectively dephosphorylating Rab proteins. Elife. 2019; 8. PMC: 6850886. DOI: 10.7554/eLife.50416. View

2.
Eguchi T, Kuwahara T, Sakurai M, Komori T, Fujimoto T, Ito G . LRRK2 and its substrate Rab GTPases are sequentially targeted onto stressed lysosomes and maintain their homeostasis. Proc Natl Acad Sci U S A. 2018; 115(39):E9115-E9124. PMC: 6166828. DOI: 10.1073/pnas.1812196115. View

3.
Fell M, Mirescu C, Basu K, Cheewatrakoolpong B, DeMong D, Ellis J . MLi-2, a Potent, Selective, and Centrally Active Compound for Exploring the Therapeutic Potential and Safety of LRRK2 Kinase Inhibition. J Pharmacol Exp Ther. 2015; 355(3):397-409. DOI: 10.1124/jpet.115.227587. View

4.
Vides E, Adhikari A, Chiang C, Lis P, Purlyte E, Limouse C . A feed-forward pathway drives LRRK2 kinase membrane recruitment and activation. Elife. 2022; 11. PMC: 9576273. DOI: 10.7554/eLife.79771. View

5.
Sobu Y, Wawro P, Dhekne H, Yeshaw W, Pfeffer S . Pathogenic LRRK2 regulates ciliation probability upstream of tau tubulin kinase 2 via Rab10 and RILPL1 proteins. Proc Natl Acad Sci U S A. 2021; 118(10). PMC: 7958464. DOI: 10.1073/pnas.2005894118. View